ProVerum’s CFO Hire Signals a New Playbook for Medtech Dominance

DUBLIN – June 08, 2026 – In a move that speaks volumes about its ambitions, Dublin-based ProVerum has appointed Jesse Litwak, a seasoned finance executive from the halls of medtech giant Medtronic, as its new Chief Financial Officer. While executive appointments are routine, this one is a clear strategic signal. ProVerum, armed with a recently FDA-approved device and a war chest of over $114 million in funding, is officially transitioning from a promising R&D innovator to an aggressive commercial contender in the multi-billion-dollar market for benign prostatic hyperplasia (BPH) treatments.

Litwak’s appointment is the kind of calculated move that strategists watch closely. It’s less about bookkeeping and more about architecting a financial future. For ProVerum, which is aiming to disrupt a market affecting over 12 million men in the U.S. alone, bringing in a leader who has managed the financial intricacies of a $6 billion global surgical business is a definitive statement of intent. The company is not just aiming to participate; it's building the leadership team to dominate.

An Architect for Aggressive Scale

Jesse Litwak is not a typical startup CFO. His 16-year tenure at Medtronic, culminating in his role as VP of Finance and CFO for its massive global Surgical business, provides him with a rare perspective. He has operated at a scale most growth-stage companies can only dream of, overseeing complex financial planning, M&A strategy, and global business unit finances. This experience is precisely what a company like ProVerum needs at this pivotal moment.

Following a landmark $80 million Series B funding round in late 2025—led by heavyweights like MVM Partners and OrbiMed—ProVerum is exceptionally well-capitalized. However, capital alone doesn't guarantee success. The challenge now is deployment: scaling manufacturing, building a world-class commercial sales force, and navigating the reimbursement landscape. Litwak’s background suggests he is the architect hired to design and execute this very playbook. His experience isn't just with large corporations; prior roles at startup ATS Medical (which Medtronic acquired) and Boston Scientific/Guidant give him a cradle-to-goliath understanding of the medtech lifecycle.

"Jesse brings a rare blend of experience from both early-stage commercial companies and large, global, publicly traded organizations," said Paul Bateman, CEO of ProVerum. "He understands what it takes to scale a business in medtech, and his leadership across finance, strategy, and M&A will be invaluable as we continue to build ProVerum." The message is clear: Litwak is here to manage hyper-growth and chart a course through the complex strategic options ahead, which could include further funding rounds, a future IPO, or positioning the company as a prime acquisition target.

Entering a Crowded and Lucrative Arena

The opportunity ProVerum is chasing is substantial. The global BPH treatment market was valued at nearly $12.5 billion in 2024 and is projected to swell to over $21 billion by 2034. This growth is fueled by an aging global population and a significant shift in patient and physician preference towards less invasive procedures. For decades, the standard was transurethral resection of the prostate (TURP), an effective but highly invasive surgery with significant side effects and long recovery times.

This created a market vacuum for innovation, which has been filled by a new generation of minimally invasive surgical therapies (MISTs). ProVerum’s ProVee System enters a competitive field against established players like Teleflex’s UroLift, a prostatic urethral lift, and Boston Scientific’s Rezum, which uses steam to ablate tissue. These technologies have already proven the market's appetite for alternatives to surgery and long-term medication.

ProVerum's strategy hinges on differentiating its ProVee System within this sophisticated market. Its success will depend not just on clinical superiority but on commercial execution and securing a strong foothold among urologists. This is where a CFO with deep market experience becomes a competitive advantage, helping to model the financial strategy for market penetration against well-entrenched competitors.

The Promise of 'Ultra Minimally Invasive' Technology

ProVerum’s confidence stems from its core technology. The ProVee System, which received FDA approval in late 2025, is an "ultra minimally invasive" prostatic stent. Deployed in an office-based procedure that can be performed under local anesthesia, the nitinol device gently expands and reshapes the prostatic urethra, relieving the obstruction that causes the disruptive symptoms of BPH—urinary frequency, urgency, and weak stream.

What sets it apart, according to the company’s clinical data, is its method. Unlike competitors, ProVee does not require cutting, burning, or ablating tissue. This was validated in the pivotal ProVIDE trial, a randomized, double-blind study that showed significant and durable symptom relief while, crucially, preserving sexual function. The study reported no device- or procedure-related serious adverse events, a critical data point for both patients and physicians weighing treatment options. The device is also retrievable, adding another layer of safety and flexibility.

This clinical profile positions ProVee as a potential first-line interventional therapy, slotting in after lifestyle changes and medication but before more invasive procedures. By offering significant relief without the side-effect profile of other interventions, ProVerum is betting it can expand the market, compelling more of the millions of men managing BPH to seek a procedural solution that promises a high quality of life.

A Playbook for the Future of Medtech

Litwak’s move from Medtronic to ProVerum is emblematic of a powerful current in the global commerce of technology. As capital flows towards proven innovators, top-tier talent follows, seeking to apply large-scale strategic experience to agile, high-growth environments. For venture-backed companies like ProVerum, which spun out of Trinity College Dublin, successfully navigating the journey from lab to market leader requires this exact fusion of disruptive technology and seasoned corporate leadership.

The appointment of a CFO with Litwak’s pedigree is the final piece of the puzzle following successful clinical trials, FDA approval, and a major funding round. It signals that ProVerum’s leadership is now focused on building a durable, competitive, and highly valuable enterprise. With the financial architecture now being put in place, the company is poised to accelerate its commercial launch and challenge the established order in one of medtech’s most dynamic markets.